RNS Number: 4228 R Shield Therapeutics PLC 30 June 2020 Shield Therapeutics plc. London, UK, 30 June 2020: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ®/ Accrufer ®, confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule...
Shield Therapeutics Plc (STX.L) Announced that it has appointed Dr. Christian Schweiger as a Non-Executive Director of the Company with immediate effect. #STX
RNS Number: 1299 R Shield Therapeutics PLC 26 June 2020 Shield Therapeutics plc. London, UK, 26 June 2020: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ®/ Accrufer ®, announces the appointment of Dr. Dr Schweiger is also Lecturing Professor in Pharmaceutical...
RNS Number: 4162 Q Shield Therapeutics PLC 18 June 2020 Shield Therapeutics plc. Results of 2020 Annual General Meeting. London, UK, 18 June 2020: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ®/ Accrufer ®, announces the results of the voting for each of the...
RNS Number: 7394 O Shield Therapeutics PLC 03 June 2020 Shield Therapeutics plc. Feraccru ®/ Accrufer ® publications. London, UK, 3 June 2020: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ®/ Accrufer ®, notes the recent publication of two papers concerning...
RNS Number: 3881 O Shield Therapeutics PLC 29 May 2020 Shield Therapeutics plc. London, UK, 29 May 2020: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ®/ Accrufer ®, confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6....
RNS Number: 1368 O Shield Therapeutics PLC 28 May 2020 Shield Therapeutics plc. London, UK, 28 May 2020: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ®/ Accrufer ®, will be presenting at two investor presentations next month, providing an overview of the business and...
Shield Therapeutics Plc #STX Announced the appointment of Hans Peter Hasler as a Non-Executive Chairman of the company with effect from the Annual General Meeting (AGM) on 18 June 2020.
RNS Number: 8330 N Shield Therapeutics PLC 26 May 2020 Shield Therapeutics plc. London, UK, 26 May 2020: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ®/ Accrufer ®, announces the appointment of Hans Peter Hasler as non-executive Chairman of the Company with effect...
RNS Number: 8031 N Shield Therapeutics PLC 22 May 2020 Shield Therapeutics plc. 2019 Annual Report and 2020 AGM Notice. London, UK, 22 May 2020: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ®/ Accrufer ®, a novel oral iron treatment, announces that the following...
Shield Therapeutics Plc #STX Announced, in its preliminary results for the year ended 31 December 2019, that revenues fell to £0.7 million from £11.9 million posted in the same period preceding year. The company’s loss before tax stood at £9.1 million, compared to a loss of £5.2 million reported in the previous year. The basic and diluted loss per share stood at £0.08 compared to loss of £0.02 reported in the previous year. The company’s cash and cash equivalents stood at £4.1 million (2018: £9.8 million).
London, UK, 21 May 2020: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ®/ Accrufer ®, announces its preliminary Group results for the year ended 31 December 2019.. ·Loss for the year of £8.8 million. ·Net cash of £4.1 million.
RNS Number: 2686 N Shield Therapeutics PLC 19 May 2020 Shield Therapeutics plc. London, UK, 19 May 2020: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ®/ Accrufer ®, a novel oral iron treatment, will announce its preliminary results for the year ended 31 December 2019...
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    117.19M

Featured Media

Company Profile

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group’s lead product, Feraccru®/Accrufer® has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland. In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV and in the USA the product will be marketed as Accrufer® with Shield currently in the process of selecting a commercialisation partner.

Classification

Market Indices-
Watchlist